Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima, Hiroshi Obaishi, Kazuki Miyazaki, Katsuji Nakamura, Osamu Tohyama, Taro Semba, Atsumi Yamaguchi, Sachi Suzuki Hoshi, Fusayo Mimura, Toru Haneda, Yoshio Fukuda, Jun-Ichi Kamata, Keiko Takahashi, Masayuki Matsukura, Toshiaki Wakabayashi, Makoto Asada, Ken-Ichi Nomoto, Tatsuo Watanabe, Zoltan Dezso, Kentaro Yoshimatsu, Yasuhiro Funahashi, Akihiko Tsuruoka
BACKGROUND: Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor α (PDGFR α), RET and KIT. Antiangiogenesis activity of lenvatinib in VEGF- and FGF-driven angiogenesis models in both in vitro and in vivo was determined. Roles of tumor vasculature (microvessel density (MVD) and pericyte coverage) as biomarkers for lenvatinib were also examined in this study...
2014: Vascular Cell